← Back to Search

Nurse-Led Telemonitoring for Chronic Conditions

N/A
Recruiting
Led By Emily Seto, PhD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have been discharged from hospital within 2 weeks during their recruitment into the study (or will be recruited prior to their discharge)
18 years of age or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months and at 1-year
Awards & highlights
No Placebo-Only Group

Summary

This trial will help bridge the gap in treatment of seniors with multiple chronic conditions by introducing nurse-led integrated care model & telemonitoring to improve coordination & self-care.

Who is the study for?
The SMaRT Study is for adults over 18 who have recently been discharged from certain hospitals in Canada and have at least one chronic condition like heart failure, COPD, high blood pressure, diabetes, or depression. Participants need to be able to use the telemonitoring app and devices (like a weight scale) and speak English or have someone who can communicate for them.
What is being tested?
This study tests the SMaRT Clinic model which uses nurse-led care coordinated through telemonitoring to manage patients with multiple chronic conditions after they leave the hospital. It aims to improve self-care education and clinical coordination across patient care teams.
What are the potential side effects?
Since this trial involves a healthcare service intervention rather than medication, traditional side effects are not applicable. However, participants may experience issues related to using technology such as privacy concerns or technical difficulties.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was discharged from the hospital less than 2 weeks ago or will be before joining the study.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months and at 1-year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months and at 1-year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
All-cause mortality
Days alive and out-of-hospital
Death and/or all-cause unplanned readmission
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Telemonitoring (Medly MCC)Experimental Treatment1 Intervention
Medly is a smartphone application allows patients with heart failure, diabetes, depression, hypertension, and/or COPD to measure and record their daily self-reported symptoms. This monitoring information is then transmitted wirelessly to a data server where an algorithm is used to generate an alert to a healthcare provider as necessary. The patient also receives an automated self-care message based on their measurements and reported symptoms.
Group II: ControlActive Control1 Intervention
Control groups will be compared to 350 patients who received standard of care via propensity-matched controls from the ICES provincial database.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Medly
2016
N/A
~100

Find a Location

Who is running the clinical trial?

Markham Stouffville HospitalOTHER
3 Previous Clinical Trials
2,117 Total Patients Enrolled
Health Sciences NorthOTHER
5 Previous Clinical Trials
762 Total Patients Enrolled
University Health Network, TorontoLead Sponsor
1,521 Previous Clinical Trials
502,954 Total Patients Enrolled
10 Trials studying Diabetes
2,688 Patients Enrolled for Diabetes

Media Library

Telemonitoring (Medly MCC) Clinical Trial Eligibility Overview. Trial Name: NCT05543720 — N/A
Diabetes Research Study Groups: Control, Telemonitoring (Medly MCC)
Diabetes Clinical Trial 2023: Telemonitoring (Medly MCC) Highlights & Side Effects. Trial Name: NCT05543720 — N/A
Telemonitoring (Medly MCC) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05543720 — N/A
~93 spots leftby Sep 2025